Intended for healthcare professionals


What should be done about mephedrone?

BMJ 2010; 340 doi: (Published 24 March 2010) Cite this as: BMJ 2010;340:c1605

This article has a correction. Please see:

  1. Adam R Winstock, senior lecturer in addiction psychiatry 1,
  2. John Marsden, reader in addiction psychology1,
  3. Luke Mitcheson, consultant clinical psychologist2
  1. 1Institute of Psychiatry, King’s College London, London SE5 8AF
  2. 2South London and Maudsley NHS Trust, London SE5 8AZ
  1. adam.winstock{at}

    We should focus on crafting the most effective public health response

    The recent deaths of two young men who are thought to have taken the β keto-amphetamine stimulant mephedrone (4-methylmethcathinone) have prompted urgent calls for the drug to be banned. As we write, there is no certainty that mephedrone caused these two deaths, but it may be implicated. Amphetamine-type stimulants are known to cause about 100, mostly accidental, deaths a year in the United Kingdom.1 Stimulant related deaths typically result from a sympathomimetic toxidrome—a constellation of symptoms and signs that can be seen with excessive consumption of stimulant type drugs—accompanied by cardiac conduction problems, cerebral haemorrhage, and sometimes hyperpyrexia. Other drugs and alcohol are commonly used at the same time,1 and may have been in the latest cases. Most drug related deaths (about 1100 cases a year in the UK) involve one or more central nervous system depressants—including opioids, alcohol, and sedatives—at doses that cause respiratory depression.2

    Almost unheard of two years ago, mephedrone—colloquially known as “Miaow,” “4-MMC,” “Meph,” and “TopCat”—has grown quickly in popularity and is now widely available for purchase online. So called “legal highs” have been available for decades, but recently web based marketing has facilitated their profitable sale. It is hard to determine the risks …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription